ImmunityBio (IBRX) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ImmunityBio (IBRX) has outperformed Protagonist Therapeutics (PTGX) over the past year, gaining 291.7% versus a gain of 114.3%. Over five years, PTGX leads with a +351.8% price change compared with +6.6% for IBRX. ImmunityBio is the larger company by market cap ($11.14 billion vs $9.30 billion), about 1.2 times the size.
Protagonist Therapeutics converts more of its revenue into profit, with a net margin of -282.8% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | PTGX |
|---|---|---|
| Share price | $10.51 | $143.73 |
| Market cap | $11.14B | $9.30B |
| 1-day change | +6.05% | +2.73% |
| YTD return | +400.51% | +60.19% |
| 1-year return | +291.70% | +114.26% |
| 5-year return | +6.56% | +351.76% |
| P/E ratio (TTM) | — | 139.54 |
| EPS (TTM) | $-0.96 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | $46.02M |
| Revenue growth (YoY) | +668.31% | -89.41% |
| Net income (latest FY) | $-351.40M | $-130.15M |
| Gross margin | 99.34% | — |
| Operating margin | -226.00% | -343.63% |
| Net margin | -310.18% | -282.83% |
| 52-week high | $12.43 | $160.81 |
| 52-week low | $1.95 | $65.75 |
| Distance from 52-week high | -15.45% | -10.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +21.31% | +21.54% |
| Average volume | 10.28M | 623.06K |
| Shares outstanding | 1.06B | 64.71M |
| Employees | 684 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed PTGX by 177.4 percentage points over the past year.
- Protagonist Therapeutics is more profitable, keeping -282.8 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs -89.41%).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
IBRX vs PTGX FAQ
Which is bigger, ImmunityBio or Protagonist Therapeutics?
ImmunityBio (IBRX) is larger, with a market capitalization of $11.14B compared with $9.30B for Protagonist Therapeutics (PTGX).
Which stock has performed better over the past year, IBRX or PTGX?
IBRX returned +291.70% over the past 12 months, compared with +114.26% for PTGX (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Protagonist Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ImmunityBio and Biotechnology: Pharmaceutical Preparations for Protagonist Therapeutics.